|MDACC Study No:||2012-0669 (clinicaltrials.gov NCT No: NCT01746836)|
|Title:||Ponatinib as Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib|
|Principal Investigator:||Jorge Cortes|
|Study Description:||The goal of this clinical research study is to learn if ponatinib can help to |
control CML in chronic phase. The safety of this drug will also be studied.
Ponatinib is designed to block the function of BCR-ABL, which is the abnormal
protein responsible for causing CML. This may cause the cancer cells to die.